Advertisement

Topics

Xavant Technology's neuromodulation device receives FDA clearance for treatment of chronic intractable pain

18:49 EDT 1 Aug 2017 | News-Medical.net

Xavant Technology (Pty) Ltd today announced that the U.S. Food and Drug Administration cleared their Stimpod NMS460. With the U.S. patent awarded on proprietary hybrid pulsed radio frequency (PRF) waveform, this non-invasive neuromodulation device is focused on the symptomatic relief and management of chronic intractable pain, as well as an adjunctive treatment in the management of post-surgical pain, post-traumatic acute pain problems, and an adjunct for pain control due to rehabilitation.

Original Article: Xavant Technology's neuromodulation device receives FDA clearance for treatment of chronic intractable pain

NEXT ARTICLE

More From BioPortfolio on "Xavant Technology's neuromodulation device receives FDA clearance for treatment of chronic intractable pain"

Quick Search
Advertisement
 

Relevant Topic

Pain
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...